The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.
 
Jingxiao Jin
No Relationships to Disclose
 
Anjali Rohatgi
Research Funding - Apollomics; Calithera Biosciences; Gilead Sciences
 
Andrew Gabrielle
No Relationships to Disclose
 
Amy Rose
No Relationships to Disclose
 
Melissa Wilson
No Relationships to Disclose
 
Tullia C. Bruno
Consulting or Advisory Role - Galvanize Therapeutics; Mestag Therapeutics; Walking Fish Therapeutics
Research Funding - Bristol Myers Squibb Foundation; Pfizer
Travel, Accommodations, Expenses - Galvanize Therapeutics; Walking Fish Therapeutics
 
John M. M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; Applied Clinical Intelligence; AXIO Research; Becker Pharmaceutical Consulting; Cancer Network; Cancer Study Group; Checkmate Pharmaceuticals; DermTech; Fenix Group International; Harbour BioMed; Immunocore; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Magnolia Innovation; Merck; Natera; OncoCyte; OncoSec; PATHAI; Pfizer; Regeneron; Replimune; Scopus BioPharma; SR One Capital Management; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron